Skip to main content
SpringerPlus

Table 5 Incidence of neutropenia

From: Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

 

EP (n = 425)

TPC (n = 406)

Number of patients with neutropenia, n (%)

111 (26.1)

174 (43.1)

 Grade 1–2

70 (16.5)

50 (12.3)

 Grade 3

32 (7.5)

79 (19.5)

 Grade 4

9 (2.1)

45 (11.1)

 Grade 5

0 (0)

1 (0.2)

  1. A composite term encompassing neutropenia, febrile neutropenia, neutropenic sepsis, and neutrophil count decreased
Back to article page